Top Markets
#1 Gama Token Gama Token +8.43%
#2 Palladium Network Palladium Network +5.79%
#3 Akedo Akedo +4.75%
#4 Cross Cross +4.45%
#5 Audiera Audiera +4.11%
#6 Humanity Humanity +3.25%
#7 Perle Perle +3.24%
#8 BNB Attestation Service BNB Attestation Service +2.64%
#9 OKZOO OKZOO +2.56%
#10 Velvet Velvet +2.46%
Coin of the day
Gama Token Gama Token
Settings
Language
ENGLISH
Currency
USD
Theme
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Rank in Stocks #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
0.00%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)

Category

Healthcare
Number of shares outstanding for Eiger BioPharmaceuticals, Inc. (EIGR)
Number of shares outstanding as of August 2026: 0
According to Eiger BioPharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Eiger BioPharmaceuticals, Inc. (EIGR) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE